## **Reply to the letter to the editor "Stenosis severity indices cannot reflect lumen loss in stent trials"**



**Taku Asano**<sup>1,2</sup>, MD; Yoshinobu Onuma<sup>3,4</sup>, MD, PhD; Johan H.C. Reiber<sup>5</sup>, PhD; Patrick W. Serruys<sup>6\*</sup>, MD, PhD

 Academic Medical Center, Amsterdam-Zuidoost, the Netherlands; 2. St. Luke's International Hospital, Tokyo, Japan;
Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands; 4. Cardialysis BV, Rotterdam, the Netherlands; 5. Department of Radiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; 6. Imperial College London, London, United Kingdom

We appreciate the interest shown by Lauri et al in the PIONEER QFR substudy<sup>1</sup>. We analysed quantitative flow ratio (QFR) at three different time points (pre-procedure, post-procedure and at nine months after the index procedure) and compared the functional significance between the BuMA<sup>TM</sup> sirolimus-eluting stent (SINOMED, Tianjin, China) and Resolute<sup>™</sup> zotarolimus-eluting stent (Medtronic, Minneapolis, MN, USA). There was no need for concern regarding preprocedural QFR because, at pre-procedure, mean diameter stenosis (DS) was 60.1±10.3% for BuMA and 60.7±10.8% for Resolute. Post-procedure and at nine months after the index procedure, mean DS ranged between 9% and 17%. As Lauri et al pointed out, QFR lacks evidence for feasibility in mild lesions; major QFR validation trials such as FAVOR pilot, FAVOR II China, FAVOR II Europe/JAPAN and the WIFI II trial excluded mild stenosis (%DS <30% by visual estimation). Visual estimation tends to overestimate stenosis compared to quantitative coronary angiography (QCA); therefore, lesions with mild stenosis (DS <30% on QCA) might have been enrolled in those trials.

The basic mathematical formula used in QFR, however, was developed and validated in non-stenotic and mild stenosis models. QFR calculation is based on the historically well-known formula that was first reported by Young et al<sup>2-4</sup>. This formula predicts a pressure drop across the stenosis by using minimum cross-sectional area, reference area, lesion length and flow velocity. Afterwards, Gould and colleagues simplified this formula as described below. This formula has already been validated in dog models of various degrees of stenosis (no stenosis, mild, moderate and severe stenosis)<sup>5</sup>:

## $\Delta p = FV + SV^2$

where F is the coefficient of pressure loss due to viscous friction and is dependent on the length, relative percent stenosis, and absolute diameter of the stenosis; S is the coefficient of pressure loss due to flow separation and is dependent on relative percent stenosis and the divergence angle of the stenosis (e.g., no stenosis  $F=0.193\pm0.067$ ,  $S=0.0013\pm0.0029$ ; mild stenosis  $F=0.272\pm0.172$ ,  $S=0.009\pm0.0032$ ).

\*Corresponding author: Cardiovascular Science Division of the NHLI within Imperial College of Science, Technology and Medicine, South Kensington Campus, London, SW7 2AZ, United Kingdom. E-mail: patrick.w.j.c.serruys@gmail.com

EuroIntervention 2018;14:839-840

Unlike QFR, the physiological assessment by FFR for mild stenosis has already been clinically applied. It has been demonstrated that FFR measured immediately after percutaneous coronary intervention is significantly associated with future adverse events<sup>6-8</sup>. In those studies, the cut-off values of FFR predicting target vessel failure ranged between 0.90 and 0.92, which is in line with QFR values in our study (QFR post procedure:  $0.92\pm0.05$  for BuMA,  $0.93\pm0.05$  for Resolute).

We believe that our approach is theoretically appropriate from the physiological point of view. As Gould et al reported in the dog model, subtle lumen loss does not impact on coronary blood flow if the stenosis remains mild (DS <50%)<sup>9</sup>. A small difference in LLL or %DS, even though it becomes statistically significant, does not have clinical significance when these parameters remain low.

## Conflict of interest statement

J. Reiber is the CEO of Medis medical imaging systems bv, and has a part-time appointment at Leiden University Medical Center as Professor of Medical Imaging. The other authors have no conflicts of interest to declare.

## References

1. Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez-Romo A, Janssens L, Smits PC, Wykrzykowska JJ, Ribeiro VG, Pereira H, da Silva PC, Piek JJ, Reiber JHC, von Birgelen C, Sabaté M, Onuma Y, Serruys PW. Functional comparison between BuMA Supreme biodegradable polymer sirolimus-eluting and durable polymer zotarolimus-eluting coronary stents using quantitative flow ratio: PIONEER QFR substudy. *EuroIntervention*. 2018;14:e570-9.

2. Young DF, Tsai FY. Flow characteristics in models of arterial stenoses. I. Steady flow. *J Biomech*. 1973;6:395-410.

3. Young DF, Tsai FY. Flow characteristics in models of arterial stenoses. II. Unsteady flow. *J Biomech*. 1973;6:547-59.

4. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv.* 2016;9:2024-35.

5. Gould KL. Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation. *Circ Res.* 1978;43:242-53.

6. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, Morel O, Lefrancois Y, Descotes-Genon V, Silvain J, Braik N, Chopard R, Chatot M, Ecarnot F, Tauzin H, Van Belle E, Belle L, Schiele F. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). *Circulation*. 2016;134: 906-17.

7. Piroth Z, Toth GG, Tonino PAL, Barbato E, Aghlmandi S, Curzen N, Rioufol G, Pijls NHJ, Fearon WF, Juni P, De Bruyne B. Response by Piroth et al to Letter Regarding Article, "Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation". *Circ Cardiovasc Interv.* 2017 Oct;10(10).

8. Li SJ, Ge Z, Kan J, Zhang JJ, Ye F, Kwan TW, Santoso T, Yang S, Sheiban I, Qian XS, Tian NL, Rab TS, Tao L, Chen SL. Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study. *JACC Cardiovasc Interv.* 2017;10:986-95.

9. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. *Am J Cardiol*. 1974;33:87-94.